Drug Approval | January 28, 2022
European Commission approves Merck’s KEYTRUDA as adjuvant therapy for RCC
KEYTRUDA is now approved as monotherapy for adults with Renal Cell Carcinoma (RCC)
KEYTRUDA is now approved as monotherapy for adults with Renal Cell Carcinoma (RCC)
The companies will continue with their exclusive agreements, including commercialization of their current portfolio
The award was given as a result of NASSCOM's meticulous screening process, in which over 700 start-ups were shortlisted as the most promising companies of the year
The vaccines are currently only authorised for emergency use in the country
It meets stringent requirements for ensuring the safe storage and efficacy of temperature-sensitive vaccines, including those for Covid-19
CEQUA’s nanomicellar (NCELL) technology improves the bioavailability and physicochemical stability of cyclosporine to increase ocular tissue penetration
According to IQVIA sales data for the 12-month period ending November 2021, the Ziac tablets, 2.5 mg/6.25 mg, 5 mg/6.25 mg, and 10 mg/6.25 mg market achieved annual sales of approximately US $ 30.3 million
This will evaluate the immunogenicity, safety, and reactogenicity of a single booster dose in adults aged 18 years and older
Urges them to focus on tele-consultation like eSanjeevani and efficient monitoring of those in home isolation
Torrent Pharmaceuticals has reported consolidated financial results for the period ended December 31, 2021.
Subscribe To Our Newsletter & Stay Updated
